Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. Its lead product candidate, Eli-002, leverages a proprietary Amphiphilic TLR9 Agonist to elicit robust immune responses against various cancer types, aiming to enhance patient outcomes. By concentrating on personalized cancer vaccines and groundbreaking immunotherapeutic approaches, Elicio Therapeutics is uniquely positioned to tackle significant unmet clinical needs in oncology, while advancing its compelling pipeline through rigorous clinical trials that could redefine the standard of cancer care.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-38.17M |
| Operating Margin | 0.00% |
| Return on Equity | -315.30% |
| Return on Assets | -70.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.72 |
| Price-to-Book | 4.78 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.61 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $27.09M |
| Float | $19.21M |
| % Insiders | 26.17% |
| % Institutions | 20.91% |
Volatility is currently expanding
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today reported financial results for the quarter ended September 30, 2026, and provided recent corporate and clinical updates.
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, November 11, 2026, at 2:30 PM ET. To register, click here.
Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer's (“SITC”) Annual Meeting. The meeting will take place November 4-8, 2026 in Phoenix, Arizona.
BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P), presented in a late-breaking Proffered Paper oral session at the European Society for Medical Oncology (“ESMO”) Congress 2026 in Madrid, Spain, and simultaneously published in Nature Medicine: "Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial".
New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancer Findings are expected to inform a refined Phase 3 development strategy BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that new pre-specified analyses from the randomized Phase 2 AMPLIFY-7P study of ELI-002 7P in resected pancreatic ductal adenocarcinoma (“PDAC”) have been selected for a late-breaking Proffered Paper oral presentation at the European Society for Medical Oncology (“ESMO”) Congress 2026, being held October 23–27, 2026, in Madrid, Spain.
BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York.
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.
Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the closing of its previously announced registered direct offering (the “Offering”) pursuant to a definitive securities purchase agreement led by two new fundamental institutional investors with participation from a large existing shareholder for the purchase of an aggregate of 4,380,313 shares of its common stock. The gross proceeds to the Company were approximately $15 million, before deducting placement agents' fees and other Offering expenses. Elicio intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities, to primarily fund the planned Phase 1 clinical development of ELI-002 7P in metastatic PDAC and Elicio's pipeline and platform, as well as for working capital and general corporate purposes.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ELTX and any ticker you trade — then tracks every position and per-strategy win rate.
